Shares of Extendicare Inc. (TSE:EXE - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$13.43 and traded as low as C$13.21. Extendicare shares last traded at C$13.31, with a volume of 123,289 shares.
Analyst Ratings Changes
A number of research analysts recently issued reports on EXE shares. National Bank Financial upgraded shares of Extendicare to a "strong-buy" rating in a research report on Wednesday, July 16th. National Bankshares lifted their price target on shares of Extendicare from C$15.45 to C$16.10 and gave the company an "outperform" rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of C$14.15.
Read Our Latest Stock Report on EXE
Extendicare Stock Performance
The company's 50 day moving average price is C$13.00 and its 200-day moving average price is C$13.44. The stock has a market cap of C$1.12 billion, a P/E ratio of 13.91 and a beta of 0.85. The company has a debt-to-equity ratio of 283.02, a quick ratio of 0.98 and a current ratio of 0.62.
Extendicare Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Monday, September 15th were given a dividend of $0.042 per share. The ex-dividend date of this dividend was Friday, August 29th. This represents a $0.17 annualized dividend and a dividend yield of 1.3%. Extendicare's dividend payout ratio (DPR) is currently 50.57%.
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.